Company Overview
Sunshine Biopharma, Inc. operates as a pharmaceutical entity dedicated to the research and development of life-saving medicines across various therapeutic areas, with a specific focus on oncology and antivirals within the United States and Canadian markets. The company functions within the broader Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a reliance on intellectual property and regulatory approvals to generate revenue from patented or generic formulations. As of the latest data, the firm employs a workforce of 52 individuals and holds a market capitalization of $5.00M, while reporting annual revenue of $37.32M. These valuation and revenue figures indicate that Sunshine Biopharma, Inc. operates as a micro-cap entity with a relatively small operational footprint, suggesting that the company is likely in a growth or development phase rather than a mature, cash-flow-positive stage typical of large-cap pharmaceutical peers.
Financial Health
The company reported total revenue of $37.32M over the trailing twelve months, yet this revenue generated a net income of -$5,992,637 and an EBITDA of -$4,559,393, revealing a significant gap between top-line generation and profitability that highlights a heavy cost structure associated with drug development and operations. The firm's free cash flow stands at -$6,501,533, indicating that the company is burning cash at a rate that exceeds its operating cash generation, which severely limits its financial flexibility and necessitates external financing or asset monetization to sustain operations. Despite these losses, the company maintains a gross margin of 33.0%, suggesting that the cost of goods sold is managed reasonably well relative to sales, although the operating margin of -5.6% and profit margin of -16.1% demonstrate that high operating expenses are eroding profitability at a substantial rate. On the balance sheet, Sunshine Biopharma, Inc. holds $9.31M in cash against $854,761 in debt, resulting in a debt-to-equity ratio of 3.53, which presents a complex picture of a firm with significant cash reserves but also high leverage relative to its equity base. The current ratio of 4.21 indicates strong short-term liquidity, as the company possesses more than four times the current assets necessary to cover its current liabilities. Furthermore, the return on equity is -24.3% and the return on assets is -9.9%, metrics that reveal that management is currently unable to generate positive returns on the capital invested, reflecting the ongoing losses typical of early-stage biopharmaceutical companies.
Valuation Assessment
Valuation metrics for the company show a trailing P/E ratio of 0.19 and a forward P/E of 0.01, where the near-zero forward multiple implies that the market expects earnings to remain negligible or negative in the coming period, preventing a traditional earnings-based valuation. The price-to-book ratio is recorded at 0.19, indicating that the stock trades at less than one-fifth of its book value, which suggests the market is pricing the company as a distressed asset or a speculative venture with little current tangible worth. Alternative valuation multiples such as the price-to-sales ratio of 0.13 and an EV/EBITDA of 0.75 further underscore the disconnect between current revenue generation and market price, reflecting the high risk profile associated with unprofitable biotech firms. Regarding trading range, the 52-week high is $3.90 and the 52-week low is $1.02, providing a reference point for the stock's historical volatility. The beta value of 1.64 indicates that the stock's price volatility is significantly higher than the broader market, moving approximately 64% more aggressively than the market average during periods of fluctuation.
Growth & Income
The company achieved a revenue growth rate of 11.6% year-over-year, while earnings growth is listed as N/A due to the lack of positive earnings to measure against, implying that the top-line expansion is the primary driver of company progress rather than profit improvement. Because the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute profits to shareholders, instead retaining all earnings to fund research and development activities or to cover operating deficits. This reinvestment strategy is standard for biopharmaceutical firms that prioritize capital expenditure for clinical trials and regulatory submissions over shareholder distributions. The overall growth and income profile is characterized by strong revenue expansion in a niche therapeutic sector but is fundamentally constrained by persistent negative earnings and cash flow, requiring continuous capital infusion to achieve future profitability.